Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: FDA's Approval of Sogroya May Change GH Class Management

Posted by Angela Maas on Nov 5, 2020

new-blog-image-development-2

When the FDA approved Novo Nordisk, Inc.'s Sogroya (somapacitan-beco) for the replacement of growth hormone in adults with growth hormone deficiency on Aug. 28, it became the only long-acting agent on the market, AIS Health reported.

There are seven short-acting growth hormones currently available to treat adults with growth hormone deficiency, all of them branded forms of somatropin. Differences among the products, all of which are self-administered, include the strengths available and the type of device to deliver the treatment. But all of them must be administered daily. Sogroya, which also is self-administered, is the only FDA-approved product with weekly dosing.

Mesfin Tegenu, R.Ph., president of PerformRx, LLC, points out that Sogroya "is a human growth hormone (hGH) analog — an hGH with an added albumin-binding moiety. Up until this point, all hGH products have been a recombinant product, identical copies of hGH (rhGH). The half-life of somapacitan is measured in days (two to three days) while the half-life of rhGH (somatropin) is measured in hours (approximately two-and-a-half hours). The extended half-life of somapacitan allows less frequent (weekly) dosing."

He says that payers typically have prior authorization on somatropin, with "controls including diagnostic and lab values as prerequisites." A prescription from an endocrinologist is also a "common practice."
"Somapacitan is likely to be managed similar to all the other rhGH class of drugs," Tegenu says, adding that "it is reasonable to classify it as a second-line or nonpreferred agent whose use is allowed only after a trial and failure of or other medical reason for not using a preferred daily rhGH."

For the Managed Care Biologics and Injectables Index: Q1 2020, Zitter Insights surveyed between Feb. 25 and April 1 51 commercial payers with 138.1 million covered lives, and respondents with 55% of the lives said they expect to cover at least one long-acting therapy at parity with a preferred short-acting one. Payers with 11% of the covered lives said they expected to prefer a long-acting agent over all other products.

Zitter also polled 25 endocrinologists about their anticipated reaction to the availability of a long-acting growth hormone. Three-fourths of them said they were somewhat likely and highly likely to prescribe it to patients new to therapy, and 68% said they were somewhat likely and highly likely to shift current patients to it.


Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.

Subscribe for Weekly Perspectives

Topics: Specialty, Industry Trends, Product Release, Data & Analytics